Articles

CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom; Weill Cornell Medical College, New York, NY
Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire
The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
CIMUS - Molecular Medicine and Chronic Diseases Research Centre, University of Santiago de Compostela
CIMUS - Molecular Medicine and Chronic Diseases Research Centre, University of Santiago de Compostela
The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire
The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire
CIMUS - Molecular Medicine and Chronic Diseases Research Centre, University of Santiago de Compostela
The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire
Present address: Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Department of Hematology Azienda Ospedaliera Città della Salute e della Scienza, Turin
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Haematologica Early view Sep 10, 2020 https://doi.org/10.3324/haematol.2020.262659